Arthritis/rheumatic Disorders

Does Hydroxychloroquine Improve Symptoms of Hand Osteoarthritis?

By February 20, 2018

Findings do not support the current practice of off-label use of hydroxychloroquine for treating symptomatic hand osteoarthritis.

Positive Results for Ixekizumab in the Treatment of Ankylosing Spondylitis

By February 13, 2018

Taltz demonstrated a statistically significant improvement in the signs and symptoms of AS.

ACR Issues New Position Statement on the Use of Biosimilars

By February 07, 2018

Healthcare providers should incorporate biosimilars, where appropriate, into their regimens to treat patients with rheumatic diseases.

Medical Food Used for Managing Osteoarthritis Recalled at FDA's Request

By January 29, 2018

There have been no deaths reported with the use of Limbrel.

Trans-Capsaicin Injection Gets Fast Track Status for Knee OA Pain

By January 16, 2018

CNTX-4975 works by targeting the capsaicin receptor (TRPV1) to selectively and rapidly inactivate the local pain fibers transmitting signals to the brain.

FDA Approves New Indication for Xeljanz, Xeljanz XR

By December 15, 2017

The new PsA approval was based on data from the Phase 3 OPAL Broaden, OPAL Beyond, and OPAL Balance studies.

Biosimilar Ixifi Gets FDA Approval for All Remicade Indications

By December 14, 2017

Ixifi is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor.

RAS Inhibitor Use May Cut Risk of MI in Rheumatoid Arthritis Patients

By December 08, 2017

The use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) was associated with a reduced risk of myocardial infarction (MI) among patients with rheumatoid arthritis (RA).

Taltz Approved for the Treatment of Active Psoriatic Arthritis

By December 04, 2017

Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug, such as methotrexate.

Steroid Injection Site Linked to Bone Changes in Osteoarthritis Patients

By November 29, 2017

Their results found that 22-24% of the hip injection group had new osteonecrosis vs. 5-9% of the hip control group and to 5% of the shoulder injection group.

FDA: Potentially Life-Threatening Adverse Events Linked to Limbrel

By November 22, 2017

The FDA is continuing to investigate Primus Pharmaceuticals and the manufacturing process for Limbrel, and will share updates as they become available.

Does Treating Undifferentiated Arthritis Delay RA Development?

By November 22, 2017

The primary outcome was development of rheumatoid arthritis.

Zilretta Now Available for the Management of Osteoarthritis Knee Pain

By November 20, 2017

Zilretta is the first extended-release, intra-articular injection for OA knee pain.

Enbrel Mini With AutoTouch Now Available

By November 17, 2017

The needle stays hidden during injection and a sensor can detect placement on skin. It also includes 3 difference injection speeds, a progress bar and a speaker.

New Drug-Free Therapy Available for Arthritis Pain

By November 16, 2017

The device has 14 pre-set therapy modes designed to block acute or chronic pain or to imitate exercise recovery, endurance and muscle strength.

Anti-Inflammatory Foods May Help With RA Symptoms, Progression

By November 08, 2017

Specific foods that were highlighted include dried plums, blueberries, pomegranates, whole grains, ginger, turmeric, specific oils, and teas; these foods were found to reduce inflammatory cytokines, joint stiffness, pain, and oxidative stress.

Factors Associated With Successful Biologics Tapering in RA

November 07, 2017

There were also significant differences between the groups in concomitant oral corticosteroid use (43.1 vs. 34.8% in the stable treatment and DT groups, respectively) and CRP level (1.9±2.5 vs. 1.1±1.3 respectively).

Disease-Modifying Osteoarthritis Tx Granted Fast Track Status

By October 25, 2017

There are currently no DMOADs approved for use in OA. MIV-711 is a selective inhibitor of cathepsin K, which is the principal protease involved in breaking down collagen in bones and cartilage.

Simponi Aria Approved for Psoriatic Arthritis, Ankylosing Spondylitis

By October 23, 2017

The FDA's expanded approvals were supported by data from two Phase 3 multicenter, randomized, double-blind, placebo-controlled studies (GO-VIBRANT and GO-ALIVE) that included >600 patients.

Tofacitinib Efficacy Investigated in Patients With Psoriatic Arthritis

October 20, 2017

Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs

Discontinuation Rates Examined After Switch to Biosimilar

By October 18, 2017

Study authors aimed to assess the pharmacokinetics, efficacy, immunogenicity, safety, and drug discontinuation after switching from infliximab (Remicade) to the biosimilar CT-P13 in 192 patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis in daily practice.

Zilretta Approved to Treat Osteoarthritis Knee Pain

By October 10, 2017

Phase 3 results found that Zilretta achieved statistically significant reductions on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) sections for pain, stiffness and function compared to immediate-release TCA.

FDA: More Data Needed for Sirukumab for Active RA

By September 27, 2017

The CRL indicated a request for additional clinical data in order to evaluate the safety of sirukumab in the treatment of RA.

UTI Treatment Gains Qualified Infectious Disease Product Designation

By September 21, 2017

"We expect to begin enrolling patients as early as December in a proof-of-concept Phase 2 study of omadacycline in uUTI, and an indication in this type of infection would broaden the opportunities for oral omadacycline in community-acquired infections," said Evan Loh, MD, COO and CMO of Paratek.

Efficacy of Steroid Injection Examined in Carpal Tunnel

September 21, 2017

Only the steroid group saw improvement in finger dexterity. The steroid group also had higher patient satisfaction scores and, as a group, the patients took fewer painkillers after treatment.

Long-Term Effectiveness of Adalimumab Examined in RA

By September 14, 2017

The authors reported that of the patients who continued taking adalimumab for ≥1 year, 67.0% were considered in low disease activity (LDA)/remission (CDAI ≥10).

Durolane Approved to Treat Knee Osteoarthritis Pain

By September 05, 2017

In clinical trials, treatment with Durolane effectively relieved pain and restored function for up to six months in patients with knee osteoarthritis.

Increases in BP, Hypertension Incidence Linked to Certain NSAIDs

By August 28, 2017

The PRECISION-ABPM study included 444 patients (408 with osteoarthritis; 36 RA) who had evidence of, or were at increased risk for, coronary artery disease.

FDA Reveals Stem Cell Policy Plans Amid Clinic Crackdowns

By August 28, 2017

An FDA inspection of the clinic found that adipose tissue was being processed into stromal vascular fraction (stem cells derived from body fat) which was then administered intravenously or directly into the spinal cord of patients.

Biosimilar Cyltezo Gets FDA Approval for Multiple Indications

By August 28, 2017

This marks the second approval of a biosimilar for adalimumab.